Bonmab Indications/Uses

Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of: Adult patients with advanced cancer in the large bowel, in combination with fluoropyrimidine-based chemotherapy treatment.
Adult patients with metastatic breast cancer, in combination with Paclitaxel or Capecitabine chemotherapy medicinal products.
Adult patients with advanced non-small cell lung cancer, administered together with a Platinum-containing chemotherapy regimen.
Adult patients with advanced non-small cell lung cancer when cancer cells have specific mutations of a protein called epidermal growth factor receptor (EGFR), administered in combination with Erlotinib.
Adult patients with advanced kidney cancer, administered in combination with Interferon.
Adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. When used for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, it will be administered in combination with Carboplatin and Paclitaxel.
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back at least 6 months after the last time, they were treated with a chemotherapy regimen containing a Platinum agent and will be administered in combination with Carboplatin and Gemcitabine.
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back before 6 months after the last time, they were treated with a chemotherapy regimen containing a platinum agent and will be administered in combination with paclitaxel, or topotecan, or pegylated liposomal doxorubicin.
Adult patients with relapsed glioblastoma. When used for patients with glioblastoma, it will be administered as a single agent.
Adult patients with persistent, recurrent or metastatic cervical cancer, Bevacizumab will be administered in combination with Paclitaxel and Cisplatin or alternatively, Paclitaxel and topotecan in patients who cannot receive platinum therapy.